Stock Track | Harrow Health Plunges 13.91% After Hours on Q3 Earnings Miss

Stock Track11-11

Harrow Health Inc (HROW) saw its shares tumble 13.91% in after-hours trading on Monday following the release of its third-quarter financial results for 2025. The pharmaceutical company's earnings and revenue fell short of analyst expectations, triggering a sell-off among investors.

The company reported an adjusted earnings per share (EPS) of $(0.12), significantly missing the analyst estimate of $0.26. Revenue for the quarter came in at $71.638 million, also falling short of the projected $73.705 million. These disappointing figures led to an immediate drop in Harrow's stock price, with shares initially declining 11.1% when the results were first announced.

Despite the overall negative reception, Harrow Health did report some positive metrics. The company's core gross margin stood at a robust 81%, indicating strong profitability for its primary product lines. However, the overall gross margin was lower at 75%, suggesting some pressure on the company's broader product portfolio. The discrepancy between core and overall performance may raise questions among investors about the company's product mix and operational efficiency.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169726913?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169726913","market":"sg","top_or_hot":-1,"title":"Stock Track | Harrow Health Plunges 13.91% After Hours on Q3 Earnings Miss","media":"Stock Track","content":"<p>Harrow Health Inc (HROW) saw its shares tumble 13.91% in after-hours trading on Monday following the release of its third-quarter financial results for 2025. The pharmaceutical company's earnings and revenue fell short of analyst expectations, triggering a sell-off among investors.</p>\n\n<p>The company reported an adjusted earnings per share (EPS) of $(0.12), significantly missing the analyst estimate of $0.26. Revenue for the quarter came in at $71.638 million, also falling short of the projected $73.705 million. These disappointing figures led to an immediate drop in Harrow's stock price, with shares initially declining 11.1% when the results were first announced.</p>\n\n<p>Despite the overall negative reception, Harrow Health did report some positive metrics. The company's core gross margin stood at a robust 81%, indicating strong profitability for its primary product lines. However, the overall gross margin was lower at 75%, suggesting some pressure on the company's broader product portfolio. The discrepancy between core and overall performance may raise questions among investors about the company's product mix and operational efficiency.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Harrow Health Plunges 13.91% After Hours on Q3 Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Harrow Health Plunges 13.91% After Hours on Q3 Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-11 05:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Harrow Health Inc (HROW) saw its shares tumble 13.91% in after-hours trading on Monday following the release of its third-quarter financial results for 2025. The pharmaceutical company's earnings and revenue fell short of analyst expectations, triggering a sell-off among investors.</p>\n\n<p>The company reported an adjusted earnings per share (EPS) of $(0.12), significantly missing the analyst estimate of $0.26. Revenue for the quarter came in at $71.638 million, also falling short of the projected $73.705 million. These disappointing figures led to an immediate drop in Harrow's stock price, with shares initially declining 11.1% when the results were first announced.</p>\n\n<p>Despite the overall negative reception, Harrow Health did report some positive metrics. The company's core gross margin stood at a robust 81%, indicating strong profitability for its primary product lines. However, the overall gross margin was lower at 75%, suggesting some pressure on the company's broader product portfolio. The discrepancy between core and overall performance may raise questions among investors about the company's product mix and operational efficiency.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"","article_id":"1169726913","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169726913","pubTimestamp":1762810341,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Harrow Health Inc (HROW) saw its shares tumble 13.91% in after-hours trading on Monday following the release of its third-quarter financial results for 2025. The pharmaceutical company's earnings and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc"},"translate_title":"个股追踪|哈罗健康盘后暴跌13.91%因第三季度盈利未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1},"content_text":"Harrow Health Inc (HROW) saw its shares tumble 13.91% in after-hours trading on Monday following the release of its third-quarter financial results for 2025. The pharmaceutical company's earnings and revenue fell short of analyst expectations, triggering a sell-off among investors.\nThe company reported an adjusted earnings per share (EPS) of $(0.12), significantly missing the analyst estimate of $0.26. Revenue for the quarter came in at $71.638 million, also falling short of the projected $73.705 million. These disappointing figures led to an immediate drop in Harrow's stock price, with shares initially declining 11.1% when the results were first announced.\nDespite the overall negative reception, Harrow Health did report some positive metrics. The company's core gross margin stood at a robust 81%, indicating strong profitability for its primary product lines. However, the overall gross margin was lower at 75%, suggesting some pressure on the company's broader product portfolio. The discrepancy between core and overall performance may raise questions among investors about the company's product mix and operational efficiency.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169726913","isCrawlerRequest":true}